All News

Large cohort study of hospitalized #AS shows that the leading cause of death in AS were cardiovascular, infectious, respiratory, & traumatic. Mortality risk was signif assoc w/ Elixhauser comorbidity index, CHF, & renal dz. NSAIDs did not increase risk https://t.co/6nlDxvO8pO https://t.co/V3hZq5xQ6Q
RheumNow Dr. John Cush ( View Tweet)
Sep 25, 2023
In a Medicare pop. study, #AS (1,426) pts had increased risk for Fracture, especially with increasing age (OR 2.8), historical fracture (5.24), and opioid use (1.86). Overall Fx incidence rate was 76.7per 1,000 person-years. https://t.co/7SCPrYtyhF https://t.co/Wf2qqRrVum
RheumNow Dr. John Cush ( View Tweet)
Sep 20, 2023
RheumNow Podcast square

RheumNow Podcast – with Special Guest Dr. Peter Nash (9.15.2023)

d Jack Cush, MD
Sep 15, 2023

This week, Dr. Jack Cush reviews the news with special guest, Dr. Peter Nash. They discuss COVID Autoantibodies, SpA life expectancy, HCQ, extraarticular RA and our approach to Early RA referrals and pre-clinical RA.

Read Article
AS pts, but not nr-axSpA, have a signif. shortened life expectancy w/ Increased mortality, esp. in HLA-B27+ AS WOMEN. SMR is increased in #AS (1.37) vs gen population. esp for B27+ AS (SMR 1.38) & AS women (SMR 1.77); not nr-axSpA (SMR 0.44) https://t.co/KrDpJXHnHE https://t.co/6gTAQazAo8
RheumNow Dr. John Cush ( View Tweet)
Sep 12, 2023
SAVE THE DATE! RheumNow Live will now be taking place in January! Who is joining us? https://t.co/EdrLp87Z81
RheumNow Dr. John Cush ( View Tweet)
Sep 09, 2023
nurse.referral.jpg

Woeful Rheumatology Referrals

d Jack Cush, MD
Sep 07, 2023

Early diagnosis of inflammatory arthritis (IA) is rooted in patient (self or MD) referrals. A recent analysis shows only a minority of rheumatology referrals had inflammatory arthritis, with only 21% were seen within the first 6 weeks of symptoms. 

Read Article
Study of 110 pts w/ LBP shows the Patrick-FABER test to be useful in addressing the SI jts & SpA diagnosis. It had sensitivity 76%, specificity 66%, PPV 58% & NPV 82%; & when (+) was assoc w/ inflammatory SI lesions on MRI & a SpA diagnosis https://t.co/EpisUSagO2 https://t.co/mt8XHIIprF
RheumNow Dr. John Cush ( View Tweet)
Sep 05, 2023
SAVE THE DATE! RheumNow Live will now be taking place in January! Will you be there? https://t.co/cpfWvKaR1y
RheumNow Dr. John Cush ( View Tweet)
Sep 02, 2023
UK regulatory authority (MHRA) has granted marketing authorization for Bimzelx (bimekizumab), a dual inhibitor of IL-17A & IL-17F; approved in adults w/ active psoriatic arthritis or axial spondyloarthritis (+/- MTX). Prev approved in EU June 2023 https://t.co/Hp5W1t6Acz https://t.co/6tZ1DN8TVo
RheumNow Dr. John Cush ( View Tweet)
Sep 01, 2023
SAVE THE DATE! RheumNow Live will now be taking place in January! Will you be there? https://t.co/WCfBzthXvl
RheumNow Dr. John Cush ( View Tweet)
Aug 31, 2023
Fracture Risk Quantified for Older Spondyloarthritis Patients Medicare beneficiaries with AS incur frequent bone fractures, a new study indicated, with the risk boosted by some unsurprising factors but also including one that was not expected. https://t.co/muvERz64LV https://t.co/Y7x3jFFadg
RheumNow Dr. John Cush ( View Tweet)
Aug 25, 2023
Xray,fracture,MD,physician

Fracture Risk Quantified for Older Spondyloarthritis Patients

d MedPage Today
Aug 22, 2023

Medicare beneficiaries with ankylosing spondylitis (AS) incur frequent bone fractures, a new study indicated, with the risk boosted by some unsurprising factors but also including one that was not expected.

Read Article
Retro cohort study finds COVID may incr risk of autoimmunity & risk is decr by Vax. Found Incr rates of SpA(1.32), RA (1.29), PsO(1.42), Graves' (1.30), APL (2.12), ITP (2.1), MS (2.66), vasculitis (1.46). Vax decr pemphigoid, Graves, APL, ITP, SLE https://t.co/Ln3NN6RfmZ https://t.co/VH3cia4AXr

Links:

Dr. John Cush RheumNow ( View Tweet)
Aug 21, 2023
Tildrakizumab, IL-23 mAb) was well tolerated in ankylosing spondylitis (AS) pts but did improve ASAS20 responses vs PBO. 101 pts given TIL or PBO. ASAS20 response was 74% TIL vs 80% PBO. Study was terminated at week 24 for lack of efficacy. https://t.co/1PdyDbAILs https://t.co/44O23ZVvrc

Links:

Dr. John Cush RheumNow ( View Tweet)
Aug 20, 2023
RheumNow Podcast square

Mono- and Oligo- are Different (8.18.2023)

d Jack Cush, MD
Aug 18, 2023

Dr. Jack Cush reviews the news and journal reports from RheumNow.com this past week.

Read Article
Residual Disease in Controlled Axial Spondyloarthritis Despite being in a state of remission or low disease activity (LDA) state, in patients with axial spondyloarthritis (axSpA), up to 42% may still have residual disease. https://t.co/n1OjCouvXr https://t.co/4Nn9nOaGXe

Links:

Dr. John Cush RheumNow ( View Tweet)
Aug 18, 2023
Tildrakizumab, IL-23 mAb) was well tolerated in ankylosing spondylitis (AS) pts but did improve ASAS20 responses vs PBO. 101 pts given TIL or PBO. ASAS20 response was 74% TIL vs 80% PBO. Study was terminated at week 24 for lack of efficacy. https://t.co/gje5hGAyOV https://t.co/gtMBpcQdGq

Links:

Dr. John Cush RheumNow ( View Tweet)
Aug 17, 2023
ankylosing%20spondylitis.jpg

Residual Disease in Controlled Axial Spondyloarthritis

d Jack Cush, MD
Aug 16, 2023

Despite being in a state of remission or low disease activity state, in patients with axial spondyloarthritis, up to 42% may still have residual disease.

Read Article
biosimilars,light,bulbs,different

The Adalimumab Biosimilar Glut

d Jack Cush, MD
Aug 15, 2023

In 2023, three marketed biosimilars (Actemra, Stelara, Humira) had their patents expire, opening opportunities for multiple new biosimilars; but with competition comes a word salad of new drug names, confusion and nonsensical discounts.

Read Article
Patient Perspectives on Telemedicine Use During the Pandemic Research from the COVID-19 Global Rheumatology Alliance included surveys and data gathering from rheumatology patients. https://t.co/EJ5TkiDMcJ https://t.co/xBx7OIxf9h

Links:

Dr. John Cush RheumNow ( View Tweet)
Aug 10, 2023

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2023 All Rights Reserved.

×